Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer

Dondoo, Tsogt-Ochir; Fukumori, Tomoharu; Daizumoto, Kei; Fukawa, Tomoya; Kohzuki, Miho; Kowada, Minoru; Kusuhara, Yoshito; Mori, Hideki; Nakatsuji, Hiroyoshi; Takahashi, Masayuki; Kanayama, Hiro‐omi

doi:10.21873/anticanres.11297

Cited by 27 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has a cytoplasmic and nuclear distribution [23]. It is also stained in reactive epithelial cells and inflammatory cells [22].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Mürtezaoğlu¹,

Güçer²

2017

pjp

View full text Add to dashboard Cite

In this study, we compared the diagnostic value of TROP-2 expression in distinguishing between benign and malignant thyroid lesions to those of HBME-1, CK19 and galectin-3. We selected 102 cases from our archive including 20 normal thyroid tissues, 23 follicular nodular diseases, 17 follicular adenomas, 20 follicular variant papillary carcinomas and 22 classical variant papillary carcinomas. Tissue microarrays constructed from these cases were immunohistochemically analyzed with HBME-1, CK19, galectin-3 and TROP-2. Respectively 73.8%, 83.3%, 69% and 50% of all papillary carcinomas were positive with HBME-1, CK19, galectin-3 and TROP-2. CK19 was positive respectively by 100%, 43.5% and 35.3% in cases of normal thyroid, follicular nodular diseases and follicular adenoma, while the other markers were negative. In distinguishing benign and malignant lesions, which constitutes this study, HBME-1, CK19, galectin-3 and TROP-2 were statistically significant (p < 0.001). In distinguishing cases of follicular variant papillary carcinoma from follicular nodular diseases and follicular adenoma, HBME-1 and galectin-3 were statistically significant (p < 0.001). Consequently, in this study, we found that all immunohistochemical markers were effective in distinguishing benign and malignant thyroid lesions. In determining malignancy, HBME-1 had the highest diagnostic accuracy, while CK19 was the most sensitive marker. The sensitivity increased when the markers were used together.

show abstract

“…It has a cytoplasmic and nuclear distribution [23]. It is also stained in reactive epithelial cells and inflammatory cells [22].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Mürtezaoğlu¹,

Güçer²

2017

pjp

View full text Add to dashboard Cite

show abstract

“…In vitro studies have revealed that Gal-3 can inhibit apoptosis in prostate cancer cells 29,[134][135][136] and induce T cell apoptosis 137 , tumour cell adhesion to endothelial cells 138,139 , proliferation, migration, and invasion of prostate tumour cells 127,136,140 . These findings were corroborated in vivo using tumour xenograft mouse models, in which Gal-3 inhibition with pharmacological or RNA interference (RNAi) strategies impaired tumour growth 127,136 , angiogenesis 137 , and metastasis 29,137,141 . Importantly, Gal-3 secreted from prostate cancer cells promoted prostate cancer bone metastasis 142,143 by remodelling the osteolytic bone tumour microenvironment, and Gal-3 inhibitors impaired prostate cancer metastasis in vivo in the Copenhagen rat 144 or in mouse…”

Section: [H2] Gal-3 In Prostate Cancermentioning

confidence: 99%

“…Gal-3 is an enzyme substrate for MMP-2, MMP-9, and PSA 148,149 , and its cleavage favours tumour progression in human prostate cancer 127 . Finally, Gal-3 has been linked to resistance to enzalutamide and bicalutamide anti-androgen therapy in mouse xenograft models, as its activity increases the levels of the androgen receptor (AR) and AR-target genes 136 , making this galectin a putative therapeutic target for patients with CRPC. Indeed, Gal-3 inhibitors have shown promising results in preclinical studies 137,150 .…”

Section: [H2] Gal-3 In Prostate Cancermentioning

confidence: 99%

“…Tumour cell-endothelial cell (heterotypic) aggregation and angiogenesis have been shown to be induced by Gal-1 and Gal-3 116,[137][138][139]144,145 , Gal-1 and Gal-3 promote an immune suppressive state by inducing T cell apoptosis and by Gal-1-dependent inhibition of T cell proliferation, cytotoxic activation and extravasation to the endothelium 118,119,124,137 . Finally, Gal-1, Gal-3 and Gal-7 mediate tumour cell proliferation and tumour growth in prostate cancer 121,127,133,136,155 . In bladder cancer, galectin-driven functional phenotypes are much less well established than in prostate cancer.…”

Section: [H1] Conclusionmentioning

confidence: 99%

See 1 more Smart Citation

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

et al. 2019

View full text Add to dashboard Cite

Advanced prostate and bladder cancer are two outstanding unmet medical needs for urological oncologists. The high prevalence of these tumours, lack of effective biomarkers, and limited effective treatment options highlight the importance of basic research in these diseases. Galectins are a family of β-galactoside-binding proteins that are frequently altered (upregulated or downregulated) in a wide range of tumours and have roles in different stages of tumour development and progression, including immune evasion. In particular, altered expression levels of different members of the galectin family have been reported in prostate and bladder cancers, which, together with the aberrant glycosylation patterns found in tumour cells and the constituent cell types of the tumour microenvironment, can result in malignant transformation and tumour progression. Understanding the roles of galectin family proteins in the development and progression of prostate and bladder cancer could yield key insights to inform the clinical management of these diseases.

show abstract

“…Galectin-3 has been recognized as a sensitive and reliable diagnostic approach for the preoperative identification of thyroid carcinomas [8]. The intense expression of galectin-3 has also been observed in lung, breast, colorectal, and prostate carcinomas [9,10]. Moreover, Gimm et al first showed distinct galectin-3 staining patterns in various types of PHEO with small sample sizes [11].…”

Section: Introductionmentioning

confidence: 99%

The Expression of Snail, Galectin-3, and IGF1R in the Differential Diagnosis of Benign and Malignant Pheochromocytoma and Paraganglioma

Deng

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. The aim of this study was to investigate the expression of Snail, galectin-3, and IGF1R in benign and malignant pheochromocytoma and paraganglioma (PPGL) and explore their role in the diagnosis of malignant PPGL. Methods. We retrospectively collected and analyzed surgical tumor tissue from 226 patients initially diagnosed with PPGL who underwent surgery from Jan. 2009 to Jan. 2016 at West China Hospital, Sichuan University. We observed and quantified the expression of Snail, galectin-3, and IGF1R in paraffin-embedded samples by immunohistochemical staining. Results. The significant difference in survival time among the three groups (benign PHEO, benign PGL, and potentially malignant PPGL) was compared by Kaplan-Meier survival analysis. The positive staining of Snail, galectin-3, and IGF1R in the benign PHEO group was significantly lower than that in the other three groups (P<0.001). The Kaplan-Meier survival plots indicated that the survival time of the patients with intense positive staining was significantly lower than that of the patients with weak positive staining. Conclusion. The intense expression of Snail, galectin-3, and IGF1R may be valuable indicators for the diagnosis of malignant PPGL.

show abstract

Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer

Abstract: Abstract. Background: Castration-resistant

Cited by 27 publications

References 25 publications

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

The Expression of Snail, Galectin-3, and IGF1R in the Differential Diagnosis of Benign and Malignant Pheochromocytoma and Paraganglioma

Contact Info

Product

Resources

About